Mirum Pharmaceuticals Inc
MIRM51.362USD
-0.658-1.26%
Market hours （ET）Quotes delayed by 15 min
2.54BMarket Cap
LossP/E TTM
More Details of Mirum Pharmaceuticals Inc Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development and commercialization of therapies for debilitating rare and orphan diseases. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. It is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Info
Ticker SymbolMIRM
Company nameMirum Pharmaceuticals Inc
IPO dateJul 18, 2019
CEOMr. Christopher (Chris) Peetz
Number of employees322
Security typeOrdinary Share
Fiscal year-endJul 18
Address989 East Hillsdale Boulevard, Suite 300
CityFOSTER CITY
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code94404
Phone16506674085
Websitehttps://mirumpharma.com/
Ticker SymbolMIRM
IPO dateJul 18, 2019
CEOMr. Christopher (Chris) Peetz
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
+7.00%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
35.95K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
+57.03%
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
5.65K
--
Mr. Andrew Mckibben
Mr. Andrew Mckibben
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
347.21K
+7.00%
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
-26.84%
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
104.41K
-0.80%
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
103.78K
--
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
35.95K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
18.67K
-30.74%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Livmarli
73.22M
65.62%
Bile Acid Medicines
38.36M
34.38%
License and other revenue
0.00
0.00%
Shareholding Stats
Updated: Mon, Jul 28
Updated: Mon, Jul 28
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
13.72%
Janus Henderson Investors
10.26%
BlackRock Institutional Trust Company, N.A.
6.09%
BVF Partners L.P.
5.65%
The Vanguard Group, Inc.
5.11%
Other
59.18%
Shareholders
Shareholders
Proportion
Frazier Life Sciences Management, L.P.
13.72%
Janus Henderson Investors
10.26%
BlackRock Institutional Trust Company, N.A.
6.09%
BVF Partners L.P.
5.65%
The Vanguard Group, Inc.
5.11%
Other
59.18%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.15%
Investment Advisor/Hedge Fund
33.35%
Hedge Fund
22.34%
Private Equity
14.20%
Research Firm
4.78%
Venture Capital
3.32%
Individual Investor
1.90%
Sovereign Wealth Fund
0.95%
Pension Fund
0.87%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
457
57.63M
116.34%
-5.10M
2025Q1
454
57.59M
116.38%
-4.84M
2024Q4
425
56.60M
115.52%
-10.44M
2024Q3
408
56.58M
118.52%
-12.05M
2024Q2
398
57.22M
121.33%
-10.51M
2024Q1
391
57.27M
121.82%
-5.03M
2023Q4
376
54.05M
116.10%
-4.66M
2023Q3
337
55.34M
123.03%
+4.03M
2023Q2
315
43.67M
117.43%
-6.40M
2023Q1
289
41.51M
112.21%
-7.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Frazier Life Sciences Management, L.P.
6.80M
13.72%
+3.07M
+82.21%
Mar 31, 2025
Janus Henderson Investors
5.08M
10.26%
+83.18K
+1.66%
May 30, 2025
BlackRock Institutional Trust Company, N.A.
3.02M
6.09%
-81.87K
-2.64%
Mar 31, 2025
BVF Partners L.P.
2.80M
5.65%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
2.53M
5.11%
+115.33K
+4.77%
Mar 31, 2025
Eventide Asset Management, LLC
2.53M
5.1%
-79.94K
-3.07%
Mar 31, 2025
Novo Holdings A/S
1.50M
3.03%
--
--
Mar 31, 2025
State Street Global Advisors (US)
1.49M
3.02%
+112.94K
+8.17%
Mar 31, 2025
Citadel Advisors LLC
1.45M
2.92%
-65.19K
-4.31%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.38M
2.79%
-8.29K
-0.60%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Virtus LifeSci Biotech Products ETF
2%
ALPS Medical Breakthroughs ETF
1.7%
Invesco Dorsey Wright Healthcare Momentum ETF
1.31%
Tema Heart & Health ETF
0.9%
Federated Hermes MDT Small Cap Core ETF
0.8%
First Trust Innovation Leaders ETF
0.67%
First Trust Small Cap Growth AlphaDEX Fund
0.62%
Innovator IBD 50 Fund ETF
0.5%
SPDR S&P Biotech ETF
0.48%
First Trust Small Cap Core Alphadex Fund
0.34%
View more
Virtus LifeSci Biotech Products ETF
Proportion2%
ALPS Medical Breakthroughs ETF
Proportion1.7%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.31%
Tema Heart & Health ETF
Proportion0.9%
Federated Hermes MDT Small Cap Core ETF
Proportion0.8%
First Trust Innovation Leaders ETF
Proportion0.67%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.62%
Innovator IBD 50 Fund ETF
Proportion0.5%
SPDR S&P Biotech ETF
Proportion0.48%
First Trust Small Cap Core Alphadex Fund
Proportion0.34%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
